Medsky Topics 
www.orlandosentinel.com
Novo obesity shot Wegovy helped alcoholics drink less in study
A Medsky Topics feed composed of posts covering recent news related to GLP-1 Agonists such as Semaglutide (Ozempic, Wegovy, Rybelsus), Liraglutide (Victoza), and Tirzepatide (Zepbound, Mounjaro) Powered by @medsky.network
Feed on BlueskyFeeds Stats
- 💙 Liked by 14 users
- 📅 Updated 13 days ago
- ⚙️ Provider graze.social
GLP-1 Agonists Likes over time
Like count prediction
The feed GLP-1 Agonists has not gained any likes in the last month.
Feed Preview for GLP-1 Agonists
Health Canada approves generic Ozempic from Apotex. The generic will sell for half the list price of the brand-name Ozempic which is $228 for a four-week supply, by @hannay.bsky.social @kellygrant1.bsky.social www.theglobeandmail.com/b…. via @theglobeandmail.com
www.theglobeandmail.com
Health Canada approves generic Ozempic from Apotex, country’s largest drug maker
Apotex is the first company to get approval that has a domestic manufacturing presence
0
6
17
Trump says U.S. to provide GLP-1 drugs for Medicare patients reut.rs/4eWeSwr
reut.rs
Trump says U.S. to provide GLP-1 drugs for Medicare patients
U.S. President Donald Trump said on Friday the government is moving to make GLP-1 weight-loss and diabetes drugs available to seniors enrolled in Medicare from July 1.
1
4
15
GLP-1 receptor agonists have shown promising results in preclinical models of alcohol addiction, as well as in analyses of health registries. ow.ly/1geZ50YTxJ5
ow.ly
GLP-1 Drug Significantly Reduces Problem Drinking in Individuals with AUD, Obesity
Adults with alcohol use disorder (AUD) and comorbid obesity who took once-weekly semaglutide significantly reduced their overall alcohol consumption and heavy drinking.
0
0
2
Review of GLP-1 Receptor Agonists in Psoriasis
Psoriasis is a chronic immune-mediated inflammatory disease plaqued by systemic comorbidities that increase morbidity, mortality, and treatment complexity. Obesity is a significant contributor to psoriatic disease.
buff.ly/rKDVAxr
0
0
0
Canada approves second generic version of Ozempic reut.rs/4wbUnSP
reut.rs
Canada approves second generic version of Ozempic
The Canadian health regulator said on Friday that it had approved Canada-based Apotex's generic version of semaglutide, making it the second copycat version of Danish drugmaker Novo Nordisk's blockbuster diabetes drug Ozempic authorized in the country.
0
12
32
More states consider dropping GLP-1 weight loss drugs from Medicaid missouriindependent.com/2….
missouriindependent.com
More states consider dropping GLP-1 weight loss drugs from Medicaid • Missouri Independent
Massachusetts and Rhode Island are considering dropping GLP-1 drugs for obesity treatment from their Medicaid programs, continuing a trend of states that have stopped coverage of these expensive medic...
1
2
3
TORONTO – Health Canada has approved the second generic version of brand-name Ozempic, this one manufactured by Canadian company Apotex.
www.winnipegfreepress.com
Health Canada approves 2nd generic version of Ozempic — and it's Canadian
TORONTO – Health Canada has approved the second generic version of brand-name Ozempic, this one manufactured by Canadian company Apotex.
0
0
2
FDA says there's no longer a need for mass compounding of semaglutide, tirzepatide and liraglutide. It's proposing to prohibit the practice, but is accepting comments through June 29.
My story for @medscape.com
#GLP1s #obesity #telehealth #diabetes #weightloss #Wegovy #Mounjaro
www.medscape.com
FDA Proposes End to Mass GLP-1 Compounding
The agency appears to leave a loophole for patient-specific formulations.
0
4
6
Massachusetts and Rhode Island are considering dropping GLP-1 drugs for obesity treatment from their Medicaid programs, Shalina Chatlani reports.
stateline.org/2026/04/30/…
stateline.org
More states consider dropping GLP-1 weight loss drugs from Medicaid • Stateline
Massachusetts and Rhode Island are considering dropping GLP-1 drugs for obesity treatment from their Medicaid programs, continuing a trend of states that have stopped coverage of these expensive medications. Thirteen state Medicaid programs are covering GLP-1 drugs for the treatment of obesity this year, down from 16 last year.
0
1
1
Semaglutide alcohol use disorder study published in @thelancet.com
#Medsky #addiction #therapy #CBT #psychiatry #behavioralhealth
0
1
1
Study w/NIH researchers and Copenhagen U shows weekly semaglutide dose added to CBT can help curb heavy drinking.
#addiction #mentalhealth #substanceusedisorder #GLP1s #Psychsky #NIDA
www.nih.gov
Adding weekly GLP-1 to cognitive behavioral therapy further reduces heavy drinking
Clinical trial suggests semaglutide may help patients with alcohol use disorder and obesity.
0
0
2
Med News: Genetics may influence the amount of weight people lose and the adverse effects they experience with #GLP-1 medications, according to new research.
ja.ma/4w4xIri
ja.ma
Genes May Help Explain Why People Respond Differently to GLP-1 Drugs
This Medical News article discusses findings that genetic variants may affect patients’ responses to glucagon-like peptide-1 receptor agonists such as semaglutide and tirzepatide.
0
0
4
My latest in @medscape.com: Seems that one by one the fear mongered risks about GLP1s get disproven. No increased suicide risk, no thyroid cancer risk, no blindness risk. But the loudest these days is muscle loss risk. Well guess what? No meaningful risk there either www.medscape.com/viewarti….
www.medscape.com
No Need to Worry About GLP-1-Induced Muscle Loss
Recent headlines have alarmingly stated dramatic muscle loss for patients on GLP-1s. Yoni Freedhoff, MD, explains why this is a manufactured controversy.
1
2
9
Pennsylvania already did.
It's one of four states -- along with California, New Hampshire and South Carolina -- to eliminate coverage of the drugs for weight loss in its Medicaid programs because the expense strained state budgets.
From @stateline.org
penncapital-star.com
More states consider dropping GLP-1 weight loss drugs from Medicaid. Pennsylvania already did. • Pennsylvania Capital-Star
Massachusetts and Rhode Island are considering dropping GLP-1 drugs for obesity treatment from their Medicaid programs, continuing a trend of states that have stopped coverage of these expensive medic...
1
5
3
Apple earnings, DHS shutdown, 'Ozempic breath' and more in Morning Squawk
cnb.cx
Apple earnings, DHS shutdown, 'Ozempic breath' and more in Morning Squawk
Here are five key things investors need to know to start the trading day.
0
3
6
www.thelancet.com/journal….
A small RCT showed substantial effect at lowering alcohol use. Larger studies and more safety data (e.g. pancreatitis risks) needed. Cost of Rx will need to come down also to make an impact. Stay tuned as lots more trials underway.
www.thelancet.com
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial
Semaglutide showed robust therapeutic effects in treatment-seeking participants with obesity and alcohol use disorder and this trial supports previous preclinical and clinical findings suggesting GLP-...
0
0
0
Published in @thelancet.com
Once-weekly #semaglutide versus placebo in patients with #alcohol use disorder and comorbid #obesity: a randomised, double-blind, placebo-controlled trial www.thelancet.com/journal….
#GLP-1 receptor agonists
#OpenAccess
#MedSky #EndoSky #PsychSky
www.thelancet.com
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial
Semaglutide showed robust therapeutic effects in treatment-seeking participants with obesity and alcohol use disorder and this trial supports previous preclinical and clinical findings suggesting GLP-...
1
0
0
Popular weight-loss drugs cut heavy drinking in Danish study
dlvr.it
Popular weight-loss drugs cut heavy drinking in Danish study
The study found that weekly shots of semaglutide cut alcohol cravings
1
1
4
This just in:
Semaglutide…associated with a reduction in heavy drinking
@thelancet.com
#GLP1
#medsky
Andrew Hardaway@andrewhardaway.bsky.social
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial - The Lancet www.thelancet.com/journals/lan...
www.thelancet.com
0
0
1
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial www.thelancet.com/journal….
www.thelancet.com
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial
Semaglutide showed robust therapeutic effects in treatment-seeking participants with obesity and alcohol use disorder and this trial supports previous preclinical and clinical findings suggesting GLP-...
0
0
3
First randomized trial to show Ozempic reduces alcohol consumption in people seeking treatment for alcohol use disorder. Placebo-controlled, double-blind. Participants with BMI >30 kg/m2.
thelancet.com/journals/lan...
thelancet.com
Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial
Semaglutide showed robust therapeutic effects in treatment-seeking participants with obesity and alcohol use disorder and this trial supports previous preclinical and clinical findings suggesting GLP-...
4
58
227
More states consider dropping GLP-1 weight loss drugs from Medicaid michiganadvance.com/2026/….
From @stateline.org
michiganadvance.com
More states consider dropping GLP-1 weight loss drugs from Medicaid • Michigan Advance
Massachusetts and Rhode Island are considering dropping GLP-1 drugs for obesity treatment from their Medicaid programs, continuing a trend of states that have stopped coverage of these expensive medic...
0
0
1